acute myeloid leukemia
Decitabine Shines in Study of AML Patients
Patients with acute myeloid leukemia who are older and fit who get pretreated with a 10-day regimen of decitabine ...
SEPTEMBER 28, 2022
Many Differences in Latest HIV Patient to Achieve HIV Remission With HSCT
A 66-year-old patient living with HIV and acute myeloid leukemia achieved complete remission from both his HIV and ...
JULY 27, 2022
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
Onureg, Oral Formulation of Azacitidine, Approved for AML
The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid ...
SEPTEMBER 4, 2020
FDA Approves Ivosidenib as First-Line Therapy for AML
The agency reviewed the application for ivosidenib using its Real-Time Oncology Review pilot program.
MAY 3, 2019
Tibsovo Offers Oral Option for IDH1-Positive Relapsed/Refractory AML
The FDA has approved ivosidenib (Tibsovo, Agios) for the treatment of adults with relapsed or refractory acute ...
JULY 22, 2018
FDA Approves Idhifa and RealTime IDH2 Assay for Relapsed or Refractory AML
Celgene's Idhifa was approved to treat adult patients with relapsed or refractory AML who have a specific genetic ...
AUGUST 2, 2017
Quinolones Reduce Infections, Delay Febrile Neutropenia in Relapsed/Refractory AML Patients
Treating patients with relapsed/refractory AML prophylactically with quinolones reduced the incidence of bacteremia ...
JULY 5, 2016
Vyxeos Increases Survival in High-Risk AML
Experimental treatment reduced the risk for death by 31% for older patients with secondary acute myeloid leukemia.
MARCH 28, 2016
